In the claims:

1. Canceled.

2. (Currently amended) The compound according to claim ~~1~~ 40 wherein said formula is:





3. (original)The compound according to claim 2 wherein X is R^d, R^e or R^f.

4. (currently amended) The compound according to claim ~~1~~ 40 wherein R^2 or R^4 is isobutenyl.

5. (currently amended) The compound according to claim ~~1~~ 40 where X is R^a.

6. (currently amended) The compound according to claim ~~1~~ 40 where X is R^b.

7. (currently amended) The compound according to claim ~~1~~ 40 where X is R^c.

8. (currently amended) The compound according to claim ~~1~~ 40 where X is R^d.

9. (currently amended) The compound according to claim ~~1~~ 40 where X is R^e.

10. (currently amended) The compound according to claim ~~1~~ 40 where X is R^f.

11. (currently amended) The compound according to claim ~~1~~ 40 where X is R^g.

12. (currently amended) The compound according to claim ~~1~~ 40 where R^1, R^2, R^3, R^4 or R^5 is ~~an isobutenyl~~ a methyl group.

13. (currently amended) The compound according to claim ~~1~~ 40 wherein Z is CH_3 or



14. Cancelled.

15. (currently amended) The compound according to claim ~~1~~ 40 wherein Z is a biphenyl group.

16. (currently amended) The compound according to claim ~~1~~ 40 wherein R is H or CH_3.

17. (currently amended) A pharmaceutically acceptable salt of the compound according to claim ~~14~~ 40.

18. (currently amended) The compound according to claim ~~1~~ 40 wherein AR is


, 
, 
or , optionally substituted with 1 or 2 fluorine groups.

19. (original) The compound according to claim 18 wherein AR is 
.

20. (currently amended) The compound according to claim ~~1~~ 40 wherein R is a C_1-C_{18} alkyl group.

21. (currently amended) The compound according to claim ~~1~~ 40 wherein R^2 or R^4 is isobutenyl.

22. (currently amended) A pharmaceutical composition comprising an effective amount of a compound according to claim ~~1~~ 40 optionally in combination with a pharmaceutically acceptable carrier, additive or excipient.

23. (currently amended) A method for treating ~~neoplasia~~ cancer in a patient in need thereof comprising administering to said patient an effective amount of a compound according to claim ~~1~~ 40.

24. (original) The method according to claim 23 wherein said ~~neoplasia~~ cancer is a tumor.

25. Canceled.

26. (currently amended) A method for treating a patient in need thereof for a disease or condition selected from the group consisting of hyperproliferative cell growth, restenosis following cardiovascular surgery, hyperplasia and chronic inflammatory diseases comprising administering to said patient suffering from said disease an effective amount of a compound according to claim ~~1~~ 40.

27. (original) The method according to claim 26 wherein said hyperproliferative cell growth disease or condition is hyperkeratosis, keratoderma, lichen, planus, psoriasis, warts or blisters.

28. (original) The method according to claim 27 wherein said hyperkeratosis is ichthyosis.

29. (previously presented) The method according to claim 26 wherein said hyproliferative cell growth disease or condition is psoriasis.

30. (previously presented) The method according to claim 27 wherein said warts are genital warts.

31. (original) The method according to claim 26 wherein said hyperplasia is cystic hyperplasia, nodular hyperplasia of the prostate or renal hyperplasia.

32. (original) The method according to claim 31 wherein said cystic hyperplasia is cystic hyperplasia of the breast.

33. (currently amended) A method for treating chronic inflammatory disease comprising administering to a patient in need of therapy an effective amount of a compound according claim ~~1~~ 40.

34. (original) The method according to claim 33 wherein said chronic inflammatory disease is rheumatoid arthritis or osteoarthritis.

35. (currently amended) A method of inhibiting isoprenylcysteine methyltransferase enzyme comprising exposing said enzyme to an effective amount of a compound according to claim ~~1~~ 40.

36. (currently amended) A method of inhibiting isoprenyl cysteine methyltransferase enzyme in a patient in order to treat a disease or condition modulated by said enzyme comprising administering to said patient an effective amount of a compound according claim ~~1~~ 40

37-38. (cancelled).

39. (currently amended) The method according to claim 23 wherein said ~~neoplasia~~ cancer is a cancer of the stomach, colon, rectal, liver, pancreatic, lung, breast, cervix uteri, corpus uteri, ovary, prostate, testis, bladder, renal, brain/cns, head and neck, throat, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, melanoma, acute lymphocytic leukemia, acute mylogenous leukemia, Ewings Sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms Tumor, neuroblastoma, hairy cell leukemia, mouth/pharynx, oesophagus, larynx, melanoma or kidney.

Please add the following new claims:

40. (New) A compound according to the formula:



where X is selected from the group consisting of R^a, R^b, R^c, R^d, R^e, R^f and R^g;



R^a is

where R^1 is an isobutylene group;

R^b is 

where R^2 and R^3 are independently a C_1-C_5 linear or branched-chain alkyl or alkene group;

R^c is 

where R^2 is the same as above;

R^d is 

where R^2 is the same as above and wherein said AR group is a phenyl, naphthyl, para or ortho substituted biphenyl group;

R^e is 

, where R^4 is a C_1-C_5 linear or branch-chained alkyl or alkene group, allyl or homoallyl group and R^5 is a C_1-C_5 linear or branch-chained alkyl or alkene group;

R^f is 

, where R^2 and R^3 are the same as is set forth above,

R^g is  where R^2 is the same as is set forth above;

Z is a C_1-C_{12} alkyl or alkylene group, or a group according to the structure



wherein each of said groups may be optionally substituted with one or more halogen groups;

R is H or a C_1-C_{18} alkyl group; and

pharmaceutically acceptable salts, anomers, solvates and polymorphs, thereof.

41. (New) The compound according to claim 40 wherein Z is a group according to the structure:



wherein each of said groups is optionally substituted with one or two fluorine groups.

42. (New) The compound according to claim 40 according to the chemical structure:



43. (New) The compound according to claim 40 wherein R is H or CH_3.